Fluorodopa F 18

CHEMBL3400972 Phase 4 Đã phê duyệt Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
214.2 g/mol
LogP
-2.0
Phase
4

A radioactively labeled form of a dopamine precursor used in PET imaging to assess dopamine system function in the brain. It is primarily used to help diagnose Parkinson's disease by detecting areas of reduced dopamine production. This diagnostic agent provides critical information about disease severity and progression.

Khối lượng phân tử

214,1800 g/mol

LogP

-2,00

TPSA

104,00 Ų

Lipinski RO5

Đạt

Lĩnh vực điều trị

Cơ chế tác dụng

Functions as a diagnostic agent by providing contrast enhancement or radioactive tracer activity that enables visualization of anatomical structures or physiological processes during medical imaging.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Cơ chế

Functions as a diagnostic agent by providing contrast enhancement or radioactive tracer activity that enables visualization of anatomical structures or physiological processes during medical imaging.

Cấu trúc 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

N[C@@H](Cc1cc(O)c(O)cc1[18F])C(=O)O

InChI

InChI=1S/C9H10FNO4/c10-5-3-8(13)7(12)2-4(5)1-6(11)9(14)15/h2-3,6,12-13H,1,11H2,(H,14,15)/t6-/m0/s1/i10-1

Molecular Formula

C9H10FNO4

HBD / HBA

4 / 6

Liên kết có thể quay

3

Nguyên tử nặng

15

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Câu hỏi thường gặp

A radioactively labeled form of a dopamine precursor used in PET imaging to assess dopamine system function in the brain. It is primarily used to help diagnose Parkinson's disease by detecting areas of reduced dopamine production. This diagnostic agent provides critical information about disease severity and progression.

Functions as a diagnostic agent by providing contrast enhancement or radioactive tracer activity that enables visualization of anatomical structures or physiological processes during medical imaging.

Yes, Fluorodopa F 18 is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3400972. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 56494. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Tuyên bố miễn trách y tế

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.